Sanofi stock and the expanded Regeneron alliance
Sanofi (ENXTPA:SAN) just widened its long-running partnership with Regeneron, committing to four new long-acting antibody programs and up to $8b in potential milestone payments on top of a $1b upfront fee.
The agreement keeps research leadership with Regeneron and global commercial execution with Sanofi, with both groups sharing development costs and splitting potential profits equally across the new immunology portfolio.
Sanofi’s expanded Regeneron deal lands as the share price trades at €70.61 and remains under pressure, with the 30 day share price return down 7.41% and the year to date share price return down 14.22%, while the 5 year total shareholder return of 4.76% points to only modest long run gains so far and suggests that recent momentum has been fading despite the new pipeline push.Scan how Sanofi compares to other drug makers that are pushing hard on immunology pipelines by reviewing a curated set of 126 healthcare AI stocks in one place.
Sanofi has just written a €1b cheque to double down on future immunology revenue while the share price sits on multi year weak returns. Is this the moment to commit capital, or is it better to wait for a cheaper entry before the pipeline is repriced?
Most Popular Narrative: 2.2% Undervalued
Sanofi is trading at €70.61 while the most followed narrative on the stock puts fair value at €72.23, which suggests only a modest gap between price and intrinsic worth but a much stronger focus on income strength and business resilience.
Der französische Pharmariese Sanofi bietet Anlegern derzeit eine interessante Kombination aus attraktiver Bewertung, starker Dividendenrendite und solider operativer Dynamik.
Wer jedoch ein substanzstarkes, krisenresistentes Unternehmen mit hohen Cashflows und einer starken Dividende sucht, findet in Sanofi derzeit einen attraktiven und fair bewerteten Titel.
See why 5 investors see Sanofi as 2% undervalued.
Result: Fair Value of €72.23 (UNDERVALUED)
Still, Sanofi faces real pressure if key drug patents erode faster than expected or if major immunology trials disappoint and investors reassess the income story.
Find out about the key risks to this Sanofi narrative.
Next Steps
Mixed signals on Sanofi so far? With both risk flags and upside potential in play, consider moving quickly and weighing both sides for yourself by checking the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Sanofi?
If Sanofi has your attention, do not stop there. Broaden your watchlist with a few focused stock sets that match different goals and risk levels.
- Target resilient balance sheets by scanning companies with strong fundamentals using this focused list of solid balance sheet and fundamentals (206 results).
- Pursue value opportunities by checking a curated pool of 179 high quality undervalued stocks that combine quality with attractive pricing.
- Hunt for lesser known opportunities by reviewing a hand picked group of 617 high quality undiscovered gems that may not yet be crowded trades.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com